>>Description of the research protocol "SKIPPAIN"

A 24-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of secukinumab in controlling spinal pain in patients with axial spondyloarthritis.
Phase III study| Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Arthrite Psoriasique
Brugmann identifier : SKIPPAIN
EudraCT identifier : 2017-000401-21


Involved department : Rheumatology
Principal investigator : Bentin
Sponsor : novartis
Contact : Clinical Research Unit

>This protocol was approved by the CHU Liège ethics committee.